Patients with diffuse large B-cell lymphoma often relapse after standard treatments, but those treated with CAR T-cell therapy have doubled the long-term survival rate. New CAR T-Cell Therapy Gives Patient Hope While driving the 500 miles from a client in Tennessee to his home in Michigan, Andy Parker, 59, a tool and die engineer, noticed that his lower leg was sore and swollen. He thought it might just be how he was sitting. But, an ultrasound scan revealed three blood clots in that leg and a lethal disease­ —acute lymphoblastic leukemia (ALL). Parker immediately began chemotherapy. After one round of treatment: no change. Second round: no change. After unsuccess- ful treatment at a second institution, Parker was referred to UChicago Medicine and Michael Bishop, MD, professor of medicine and an expert in CAR T-cell therapy, a type of cancer treatment that works by modifying a patient’s own immune system to kill cancer cells. After CAR T-cell therapy, Parker’s tests showed no leukemia. One month later, a second test confirmed: no cancer. He was back to work after two months and by three months, enjoying what Bishop called “a continuous complete remission.” Learn more about CAR T-cell therapy at UChicago Medicine by visiting: Andy Parker and his fiancée, Mary Welliver 15